phobar

3 ms·

1. 1.▲
   by phobar 6y ago

   Good points but you should differentiate between generics and novel therapies that make up for the 190B USD in EU sales.
2. 2.▲
   by phobar 6y ago

   You commonly sell it back to the insurance company.
3. 3.▲
   by phobar 6y ago

   Interesting, could you describe one inefficiency that was exploited in the past? I could imagine buying/selling due to spreads between exchanges but is there another not as obvious example?
4. 4.▲
   by phobar 6y ago

   I am curious, dohappen to have a source for that statement?
5. 5.▲
   by phobar 7y ago

   They are funded by several big pharma companies (from which they have learned a lot in terms of QSAR). One main point of the collaboration is the creation of production ready toolkits.